RU2017120855A - Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина - Google Patents
Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина Download PDFInfo
- Publication number
- RU2017120855A RU2017120855A RU2017120855A RU2017120855A RU2017120855A RU 2017120855 A RU2017120855 A RU 2017120855A RU 2017120855 A RU2017120855 A RU 2017120855A RU 2017120855 A RU2017120855 A RU 2017120855A RU 2017120855 A RU2017120855 A RU 2017120855A
- Authority
- RU
- Russia
- Prior art keywords
- dodeca
- triazatricyclo
- carboxamide
- triene
- pyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (10)
1. Соединение или его фармацевтически приемлемая соль, выбранное из
ИЗОМЕР 1
ИЗОМЕР 1
ИЗОМЕР 1
ИЗОМЕР 1
ИЗОМЕР 2
ИЗОМЕР 1
ИЗОМЕР 2
ИЗОМЕР 1
ИЗОМЕР 2
2. Фармацевтическая композиция, содержащая соединение по п.1 и фармацевтически приемлемый носитель.
3. Фармацевтическая композиция по п.2, содержащая, кроме того, дополнительный активный агент.
4. Способ лечения резистентности к инсулину, метаболического синдрома, метаболических нарушений, диабета или их осложнений, или повышения чувствительности к инсулину, включающий введение соединения по п.1 или фармацевтической композиции по п.2 или 3 нуждающемуся в этом субъекту.
5. Способ лечения заболеваний или расстройств, возникающих в результате уменьшения экспрессии или активности SIRT1, который включает введение соединения или его фармацевтически приемлемой соли по п.1 или фармацевтической композиции по п.2 или 3 нуждающемуся в этом субъекту.
6. Способ по п.5, где заболевания или расстройства, возникающие в результате уменьшения экспрессии или активности SIRT1 выбраны из, но ими не ограничиваются, старения или стресса, диабета, метаболических нарушений, нейродегенеративных заболеваний, сердечно сосудистого заболевания, злокачественного новообразования или воспалительного заболевания.
7. Способ по п.5, где заболевания или расстройства выбраны из псориаза, атопического дерматита, акне, розацеа, кондиломы, воспалительного заболевания кишечника, болезни Крона, язвенного колита, остеопороза, сепсиса, артрита, ХОБЛ, системной красной волчанки, фталмического воспаления, алопеции, лечения ран, глазных нарушений, сухости глаз, кератита и увеита.
8. Соединение по п.1 для применения в терапии псориаза, атопического дерматита, акне, розацеа, кондиломы, воспалительного заболевания кишечника, болезни Крона, язвенного колита, остеопороза, сепсиса, артрита, ХОБЛ, системной красной волчанки, фталмического воспаления, алопеции, лечения ран, глазных нарушений, сухости глаз, кератита или увеита.
9. Применение соединения по п.1 при изготовлении лекарственного средства для лечения псориаза, атопического дерматита, акне, розацеа, кондиломы, воспалительного заболевания кишечника, болезни Крона, язвенного колита, остеопороза, сепсиса, артрита, ХОБЛ, системной красной волчанки, фталмического воспаления, алопеции, лечения ран, глазных нарушений, сухости глаз, кератита или увеита.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462081916P | 2014-11-19 | 2014-11-19 | |
US62/081,916 | 2014-11-19 | ||
PCT/IB2015/058977 WO2016079709A1 (en) | 2014-11-19 | 2015-11-19 | Substituted bridged urea analogs as sirtuin modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2017120855A true RU2017120855A (ru) | 2018-12-19 |
Family
ID=54705247
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017120857A RU2017120857A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
RU2017120855A RU2017120855A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
RU2017120858A RU2017120858A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017120857A RU2017120857A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017120858A RU2017120858A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
Country Status (21)
Country | Link |
---|---|
US (4) | US10072011B2 (ru) |
EP (4) | EP3221317B1 (ru) |
JP (4) | JP6806679B2 (ru) |
KR (4) | KR20170083133A (ru) |
CN (4) | CN107207520A (ru) |
AU (4) | AU2015348942B2 (ru) |
BR (4) | BR112017010595A2 (ru) |
CA (4) | CA2968029A1 (ru) |
CL (1) | CL2017001275A1 (ru) |
CO (1) | CO2017004994A2 (ru) |
CR (1) | CR20170209A (ru) |
DO (1) | DOP2017000123A (ru) |
EA (1) | EA201791074A1 (ru) |
ES (1) | ES2823748T3 (ru) |
IL (1) | IL252252A0 (ru) |
MX (1) | MX2017006658A (ru) |
PE (1) | PE20171257A1 (ru) |
PH (1) | PH12017500913A1 (ru) |
RU (3) | RU2017120857A (ru) |
SG (1) | SG11201703824QA (ru) |
WO (4) | WO2016079710A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10653782B2 (en) * | 2014-11-25 | 2020-05-19 | Nortwestern University | Retroviral particles expressing Sirt1 embedded within PPCN |
CN108329388A (zh) * | 2018-01-18 | 2018-07-27 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的沉默配型信息调节蛋白突变蛋白及其应用 |
CN108707150B (zh) * | 2018-05-14 | 2021-04-16 | 江苏惠利生物科技有限公司 | 一种咪唑并吡嗪医药中间体的制备方法 |
CN108395436B (zh) * | 2018-05-14 | 2021-01-12 | 鹤壁市人民医院 | 一种咪唑并吡嗪医药中间体的制备方法 |
CN110478339A (zh) * | 2019-08-12 | 2019-11-22 | 昆明理工大学 | 紫铆因在制备靶向恢复突变p53构象药物中的应用 |
WO2021043703A1 (de) * | 2019-09-02 | 2021-03-11 | Merck Patent Gmbh | Materialien für organische elektrolumineszenzvorrichtungen |
CN114890955A (zh) * | 2022-06-23 | 2022-08-12 | 江西瑞威尔生物科技有限公司 | 一种n取代吗啉类有机化合物的制备工艺 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO2006094210A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Tetrahydroquinoxalinone sirtuin modulators |
UA108596C2 (xx) | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
ES2574927T3 (es) * | 2009-10-29 | 2016-06-23 | Glaxosmithkline Llc | Piridinas bicíclicas y análogos como moduladores de sirtuina |
WO2013090369A1 (en) * | 2011-12-12 | 2013-06-20 | Smb Innovation | Novel heterocyclic compounds useful in sirtuin binding and modulation |
KR20160006215A (ko) * | 2013-05-13 | 2016-01-18 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 가교 우레아 유사체 |
-
2015
- 2015-11-19 JP JP2017526852A patent/JP6806679B2/ja active Active
- 2015-11-19 WO PCT/IB2015/058978 patent/WO2016079710A1/en active Application Filing
- 2015-11-19 KR KR1020177016277A patent/KR20170083133A/ko unknown
- 2015-11-19 US US15/527,581 patent/US10072011B2/en not_active Expired - Fee Related
- 2015-11-19 EA EA201791074A patent/EA201791074A1/ru unknown
- 2015-11-19 RU RU2017120857A patent/RU2017120857A/ru unknown
- 2015-11-19 BR BR112017010595-0A patent/BR112017010595A2/pt not_active Application Discontinuation
- 2015-11-19 BR BR112017010601A patent/BR112017010601A2/pt not_active Application Discontinuation
- 2015-11-19 AU AU2015348942A patent/AU2015348942B2/en not_active Ceased
- 2015-11-19 KR KR1020177016278A patent/KR20170083134A/ko unknown
- 2015-11-19 CR CR20170209A patent/CR20170209A/es unknown
- 2015-11-19 JP JP2017526875A patent/JP2017534663A/ja not_active Withdrawn
- 2015-11-19 CA CA2968029A patent/CA2968029A1/en not_active Abandoned
- 2015-11-19 CN CN201580073769.9A patent/CN107207520A/zh active Pending
- 2015-11-19 CA CA2968032A patent/CA2968032A1/en not_active Abandoned
- 2015-11-19 US US15/527,851 patent/US20190048016A1/en not_active Abandoned
- 2015-11-19 KR KR1020177016279A patent/KR20170087907A/ko unknown
- 2015-11-19 AU AU2015348941A patent/AU2015348941A1/en not_active Abandoned
- 2015-11-19 BR BR112017010599A patent/BR112017010599A2/pt not_active Application Discontinuation
- 2015-11-19 WO PCT/IB2015/058980 patent/WO2016079711A1/en active Application Filing
- 2015-11-19 CA CA2968027A patent/CA2968027A1/en not_active Abandoned
- 2015-11-19 CN CN201580073897.3A patent/CN107207509B/zh not_active Expired - Fee Related
- 2015-11-19 KR KR1020177016280A patent/KR20170083135A/ko unknown
- 2015-11-19 ES ES15801271T patent/ES2823748T3/es active Active
- 2015-11-19 AU AU2015348944A patent/AU2015348944A1/en not_active Abandoned
- 2015-11-19 PE PE2017000883A patent/PE20171257A1/es not_active Application Discontinuation
- 2015-11-19 CN CN201580073782.4A patent/CN107207521A/zh active Pending
- 2015-11-19 BR BR112017010602A patent/BR112017010602A2/pt not_active Application Discontinuation
- 2015-11-19 CN CN201580073311.3A patent/CN107108627A/zh active Pending
- 2015-11-19 RU RU2017120855A patent/RU2017120855A/ru unknown
- 2015-11-19 EP EP15801271.6A patent/EP3221317B1/en active Active
- 2015-11-19 EP EP15801270.8A patent/EP3221316A1/en not_active Withdrawn
- 2015-11-19 JP JP2017526950A patent/JP2017534664A/ja active Pending
- 2015-11-19 WO PCT/IB2015/058981 patent/WO2016079712A1/en active Application Filing
- 2015-11-19 SG SG11201703824QA patent/SG11201703824QA/en unknown
- 2015-11-19 MX MX2017006658A patent/MX2017006658A/es unknown
- 2015-11-19 US US15/527,440 patent/US20170355705A1/en not_active Abandoned
- 2015-11-19 CA CA2968030A patent/CA2968030A1/en not_active Abandoned
- 2015-11-19 WO PCT/IB2015/058977 patent/WO2016079709A1/en active Application Filing
- 2015-11-19 US US15/527,941 patent/US20180319810A1/en not_active Abandoned
- 2015-11-19 JP JP2017526965A patent/JP2017534665A/ja active Pending
- 2015-11-19 RU RU2017120858A patent/RU2017120858A/ru unknown
- 2015-11-19 EP EP15816522.5A patent/EP3221322A1/en not_active Withdrawn
- 2015-11-19 AU AU2015348943A patent/AU2015348943A1/en not_active Abandoned
- 2015-11-19 EP EP15804601.1A patent/EP3220918A1/en not_active Withdrawn
-
2017
- 2017-05-11 IL IL252252A patent/IL252252A0/en unknown
- 2017-05-17 PH PH12017500913A patent/PH12017500913A1/en unknown
- 2017-05-18 DO DO2017000123A patent/DOP2017000123A/es unknown
- 2017-05-18 CL CL2017001275A patent/CL2017001275A1/es unknown
- 2017-05-19 CO CONC2017/0004994A patent/CO2017004994A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017120855A (ru) | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина | |
RU2017120859A (ru) | Замещенные мостиковые аналоги мочевины в качестве модуляторов сиртуина | |
JP2019530695A5 (ru) | ||
IL263511A (en) | H1-pyrazolo[4, 3-b]pyridines as pde1 inhibitors | |
JP2019512482A5 (ru) | ||
RU2015152576A (ru) | Производные индолин-2-она или пирролопиридин/пиримидин-2-она | |
HRP20201746T1 (hr) | Aromatski derivati sulfonamida | |
JP2012532931A5 (ru) | ||
JP2019504821A5 (ru) | ||
JP2019519484A5 (ru) | ||
RU2017105296A (ru) | Новые соединения | |
RU2015132181A (ru) | Фтор-[1,3]-оксазины в качестве ингибиторов васе1 | |
JP2016523976A5 (ru) | ||
JP2017500364A5 (ru) | ||
RU2019116251A (ru) | Пиразоло[3,4-b]пиридины и имидазо[1,5-b]пиридазины в качестве ингибиторов pde1 | |
EA018721B1 (ru) | Модуляторы сигнального пути hedgehog | |
RU2019132212A (ru) | Селективные ингибиторы hdac6 | |
JP2015500332A5 (ru) | ||
RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
RU2013145299A (ru) | Тиазолопиримидины | |
KR20170020522A (ko) | 인돌린-2-온 또는 피롤로-피리딘-2-온 유도체 | |
RU2015100942A (ru) | Производное пиперидинилпиразолпиридина | |
RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
RU2012146246A (ru) | Антибактериальные производные изохинолин-3-илмочевины | |
JP2020502230A5 (ru) |